Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression

Pancreatology

Volumn 10, Issue 5, 2010, Pages 545-552

  Funel, Niccola ^a   Costa, Francesco ^b   Pettinari, Letizia ^b   Taddeo, Adriano ^c   Sala, Alessandra ^b   Chiriva Internati, Maurizio ^d   Cobos, Everardo ^d   Colombo, Graziano ^b   Milzani, Aldo ^b   Campani, Daniela ^a   Dalle Donne, Isabella ^b   Gagliano, Nicoletta ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Department of Science and Biomedical Technologies   (Italy)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Matrix metalloproteinases; Pancreatic ductal adenocarcinoma; Secreted protein acidic and rich in cysteine; Tumor invasion

Indexed keywords

GELATINASE A; GELATINASE B; MATRIGEL; MESSENGER RNA; NSC 631570; OSTEONECTIN; UKRAIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL INVASION; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; FLOW MEASUREMENT; HUMAN; HUMAN CELL; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SUPERNATANT; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 77958116636     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000266127     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics. 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Li D, Xie K, Wolff R, Abbruzzese JL: Pancreatic cancer. Lancet 2004; 363: 1049-1057.
3. Ghaneh P, Costello E, Neoptolemos JP: Biology and management of pancreatic cancer. Gut 2007; 56: 1134-1152.
4. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
5. Liu Y, Brand RE, Turzhitsky V, Kim YL, Roy HK, Hasabou N, Sturgis C, Shah D, Hall C, Backman V: Optical markers in duodenal mucosa predict the presence of pancreatic cancer. Clin Cancer Res 2007; 13: 4392-4399.
6. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
7. Neuhaus P, Oettle H, Post S, et al.: A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. Proc Am Soc Clinical Oncology Ann Meet, 2005, abstr 4013.
8. Abbruzzese JL: New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002; 95: 941-945.
9. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, Nakamura T: Induction of hepatocyte growth factor in fibroblasts by tumorderived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 1997; 57: 3305-3313.
10. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
11. Kang Y, Massagué J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-279.
12. Kretmair H: Hypericum perforatum , St. John's wort. Pharmazie 1950; 5: 85-88.
13. Susak YM, Zemskov VS, Yaremchuk OY, Kravchenco OB, Yatsyk IM, Korsh OB: Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. Drugs Exp Clin Res 1996; 22: 115-122.
14. Uglianitsa KN, Nefyodov LI, Brzosko W: Evaluation of the efficacy of Ukrain in the treatment of breast cancer: clinical and laboratory studies. Drugs Exp Clin Res 1998; 24: 231-239.
15. Uglianitsa KN, Nechiporenko NA, Nefyodov LI, Brzosko WJ: Ukrain therapy of stage T1N0M0 bladder cancer patients. Drugs Exp Clin Res 1998; 24: 227-230.
16. Zemskov V, Prokopchuk O, Susak Y, Zemskov S, Tkachenko O, Hodysh Y, Nowicky W: Efficacy of Ukrain in the treatment of pancreatic cancer. Langenbecks Arch 2002; 387: 84-89.
17. Ernst E, Schmidt K: Ukrain - a new cancer cure? A systematic review of randomised clinical trials. BMC Cancer 2005; 5: 69.
18. Gansauge F, Ramadani M, Schwarz M, Beger HG, Lotspeich E, Poch B: The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer. Hepatogastroenterology 2007; 54: 917-920.
19. Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P, Vignati S, Codegoni A, Desiderio MA, Faircloth G, Jimeno J, D'Incalci M: Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer 2002; 86: 1510-1517.
20. Yang J, Liu Y: Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 59: 1465-1475.
21. Lee JM, Dedhar S, Kalluri R, Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981.
22. Liotta LA, Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51: 5054s-5059s.
23. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, He CS, Bauer EA, Goldberg GI: H-ras oncogene transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J Biol Chem 1988; 263: 6579-6587.
24. Strongin AY, Marmer BL, Grant GA, Goldberg GI: Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP- 2. J Biol Chem 1993; 268: 14033-14039.
25. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase: isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338.
26. Cao J, Rehemtulla A, Bahou W, Zucker S: Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem 1996; 271: 30174-30180.
27. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, Aoki T, Seiki M: Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 2001; 20: 4782-4793.
28. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck W, Wagner M, Wilda M, Friess H, Buchler M, Adler G, Gress TM: Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000; 85: 14-20.
29. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathological and prognostic significance of matrilysin expression. J Clin Oncol 2001; 19: 1118-1127.
30. Pryczynicz A, Guzinska-Ustymowicz K, Dymicka- Piekarska V, Czyzewska J, Kemona A: Expression of matrix metalloproteinase in pancreatic ductal carcinoma is associated with tumor metastasis formation. Folia Histochem Cytobiol 2007; 45: 37-40.
31. Bradshaw AD, Sage EH: SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107: 1049-1054.
32. Brekken RA, Sage EH: SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2000; 19: 569-580.
33. Wewer UM, Albrechtsen R, Fisher LW, Young MF, Termine JD: Osteonectin/ SPARC/BM-40 in human decidua and carcinoma, tissues characterized by de novo formation of basement membrane. Am J Pathol 1988; 132: 345-355.
34. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C: Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995; 64: 70-75.
35. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997; 108: 210-214.
36. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999; 30: 339-344.
37. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL: Differential expression of osteonectin/ SPARC during human prostate cancer progression. Clin Cancer Res 2000; 6: 1140-1149.
38. Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO, Kagawa S: Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001; 166: 2495-2499.
39. Yiu GK, Chan W Y, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC: SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001; 159: 609-622.
40. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopman J, Su GH, Hruban RH, Goggins M: SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and mediator of tumorstromal interactions. Oncogene 2003; 22: 5021-5030.
41. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC: Tumor- associated macrophages: the doubleedged sword in cancer progression. J Clin Oncol 2005; 23: 953-964.